AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsAbbVie is successfully transitioning its revenue base toward newer immunology drugs to offset the loss of patent protection for Humira.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.